Mavatrep (JNJ‐39439335) is a TRPV1 receptor selective competitive antagonist.

[1] It is an investigational analgesic that may be a potential treatment for pain and/or inflammation.

Phase I trials have been completed in healthy Japanese and Caucasian volunteers.

[1][2] Potential common adverse effects include thermohypoesthesia, chills, feeling cold, and feeling hot.

Mavatrep appears to be metabolized into two primary metabolites which are also eliminated nonrenally.